Colorado-based MicroPhage has received FDA clearance for its KeyPath MRSA/MSSA Blood Culture Test, which can rapidly distinguish between methicillin resistant and methicillin susceptible Staphylococcus aureus bacteria. The test "not only saves time in diagnosing potentially life-threatening infections but also allows health care professionals to optimize treatment and start appropriate contact precautions to prevent the spread of the organism," said Alberto Gutierrez, the director of the in vitro diagnostics unit at the FDA's device center.

Related Summaries